Trial Profile
A Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Motixafortide (Primary)
- Indications Stem cell mobilisation
- Focus Proof of concept; Therapeutic Use
- 23 Jun 2023 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Results evaluating the safety and efficacy of BL-8040 for the mobilization of donor haematopoietic stem and progenitor cells for allogeneic hematopoietic cell transplantation and phenotypic characterization of the leukapheresis product presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 01 Nov 2018 Planned End Date changed from 30 Dec 2023 to 12 Apr 2023.